Background-Treatment times for ST-elevation myocardial infarction (STEMI) patients presenting to percutaneous coronary intervention hospitals have improved dramatically over the past 10 years, particularly for patients using emergency medical services. Limited data exist regarding treatment times and outcomes for patients who develop STEMI after hospital admission.
The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations for the diagnosis of pulmonary hypertension. However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update y appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to non-invasive diagnosis of PH. This commentary summarizes the results and recommendations of the working group on treatment of PAH.
The 2015 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) associated with chronic lung disease. The European Guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, sGC stimulators) have not been sufficiently investigated in other forms of PH. Therefore, the European Guidelines do not recommend the use of these drugs in patients with chronic lung disease and PH. This recommendation, however, is not always in agreement with medical ethics as physicians feel sometimes inclined to treat other form of PH which may affect quality of life and survival of these patients in a similar manner. To this end, it is crucial to consider the severity of both PH and the underlying lung disease. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were initiated, one of which was dedicated to the diagnosis and treatment of PH in patients with chronic lung disease. The recommendations of this working group are summarized in the present paper.
Conclusions: Our data demonstrates that PTs with STEMI and a CTO have higher inhospital, 30 day, and one year mortalities than STEMI PTs without a CTO. PTs with NSTEACS and a CTO have higher in-hospital and 30 day mortality than NSTEACS PTs without a CTO, and there is a non-significant trend towards increased one year mortality for PTs with a CTO. Strategies to reduce this increased mortality are needed.Background: Cardiac arrest (CA) is often the result of both acute and chronic coronary artery disease (CAD) particularly when it is caused by ventricular tachycardia or fibrillation (VT/VF). Therapeutic hypothermia has been shown to decrease mortality and after resuscitated CA (rCA). It has been demonstrated that a chronic total occlusion (CTO) in the non-infarct artery in patients (Pts) with ST segment elevation myocardial infarction (STEMI) is associated with increased mortality. The incidence and effect of CTOs in Pts with rCA has not been well described. Further the incidence and effect of CTOs in rCA Pts as the result of STEMI is unknown. Methods: The Minneapolis Heart Institute has developed formalized protocols for both STEMI (Level One, L1) and cardiac arrest and sequential therapeutic hypothermia (CoolIt). From 2006-May 2012, 164 sequential Pts who had been enrolled in the Cool-It program who presented with VT/VF and underwent angiography were evaluated for the presence of at least one CTO in a major coronary vessel. From 2006-May 2012, 121 PTs who had been enrolled in the Cool-It program and underwent angiography but also suffered from STEMI were also evaluated for CTOs. In-hospital, 30 day, and 1 year mortality were compared between Pts who did and did not have CTO. STEMI Pts who presented with rCA were compared to STEMI Pts without rCA for the presence of a CTO.
Results: See table below:Conclusions: These data demonstrate that rCA Pts presenting with VT/VF and who have a CTO appear to have similar mortality compared to those without a CTO. Pts with and without a CTO who presented with rCA and STEMI have similar mortality although there is a trend in favor of those without a CTO. STEMI Pts with rCA have a higher incidence of a CTO than do STEMI Pts without rCA. Further efforts to understand, treat, and avoid CA in Pts with a CTO are warranted.
TCT-372"Full metal jacket" (stented length > or [ 50 mm) using drug-eluting stents for chronic total occlusive lesions.Background: Limited data exists on patients who have undergone drug eluting stent (DES) implantation of long chronic total occlusive (CTO) lesion in native coronary arteries. Methods: We defined long continuous stent implantation (stent length > or ¼ 50 mm) as "full metal jacket" (FMJ). From April 2007 to March 2013, 344 consecutive patients (361 lesions) who underwent FMJ using any DESs for de novo lesion were enrolled. Subjects were classified into two groups: the patients with CTO lesion (CTO group, 113 patients, 114 lesions) and without CTO lesion (non-CTO group, 239 patients, 247 lesions). The two groups were compared for mean 24AE19 months c...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.